Last reviewed · How we verify
AQX-1125
AQX-1125 is a NLRP3 inflammasome inhibitor Small molecule drug developed by Aquinox Pharmaceuticals (Canada) Inc.. It is currently in Phase 2 development for Treatment of rheumatoid arthritis.
AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.
AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome. Used for Treatment of rheumatoid arthritis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AQX-1125 |
|---|---|
| Sponsor | Aquinox Pharmaceuticals (Canada) Inc. |
| Drug class | NLRP3 inflammasome inhibitor |
| Target | NLRP3 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
The NLRP3 inflammasome is a multiprotein complex that plays a key role in the innate immune response. Inhibition of the NLRP3 inflammasome has been shown to reduce inflammation and improve symptoms in various inflammatory diseases.
Approved indications
- Treatment of rheumatoid arthritis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome (PHASE2)
- Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (PHASE2)
- Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (PHASE1)
- Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (PHASE3)
- Efficacy and Safety of AQX-1125 in IC/BPS (PHASE2)
- Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 (PHASE1)
- Efficacy and Safety of AQX-1125 in Unstable COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AQX-1125 CI brief — competitive landscape report
- AQX-1125 updates RSS · CI watch RSS
- Aquinox Pharmaceuticals (Canada) Inc. portfolio CI
Frequently asked questions about AQX-1125
What is AQX-1125?
How does AQX-1125 work?
What is AQX-1125 used for?
Who makes AQX-1125?
What drug class is AQX-1125 in?
What development phase is AQX-1125 in?
What are the side effects of AQX-1125?
What does AQX-1125 target?
Related
- Drug class: All NLRP3 inflammasome inhibitor drugs
- Target: All drugs targeting NLRP3
- Manufacturer: Aquinox Pharmaceuticals (Canada) Inc. — full pipeline
- Therapeutic area: All drugs in Rheumatology
- Indication: Drugs for Treatment of rheumatoid arthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing